RxDoctor Payments Data

Bryan Robertson, MD

Interventional Cardiology · Pittsburgh, PANPI 1114910197

Payments from drug & device makers

$1,471in general payments, 2019–2025

Across 72 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$231
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$207
  • Novartis$204
  • Johnson & Johnson$132
  • Abiomed$118
  • Kestra Medical Technology Services, Inc.$117
  • plus $462 from 12 others

What the payments were for

  • Food & beverage$1,471100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,471 in reported general payments places this provider in the 10th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$68,942
Medicare patients
692
Services billed
1,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$206,282
Repatha SureclickEvolocumab118$126,535
EntrestoSacubitril/Valsartan69$114,397
JardianceEmpagliflozin45$50,863
BrilintaTicagrelor50$36,092
XareltoRivaroxaban21$25,546
Praluent PenAlirocumab12$14,439
Atorvastatin Calcium438$6,641
Ezetimibe207$5,577
Rosuvastatin Calcium278$4,733
Metoprolol Succinate233$3,472
Diltiazem 24hr Er (Cd)Diltiazem Hcl48$3,139
Valsartan111$2,232
Labetalol Hcl48$2,058
Carvedilol164$1,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$206,282186 claims
NovartisEntresto$204$114,39769 claims
Boehringer IngelheimJardiance$63$50,86345 claims
AstraZenecaBrilinta$28$36,09250 claims
Johnson & JohnsonXarelto$132$25,54621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →